Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu-PSMA + SABR in Oligometastatic Prostate Cancer
NCT05560659Phase 2Recruiting
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Dec 2023
- Primary completion
- May 2026
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 2
01
Overview
A Phase 2 trial of lutetium lu 177 vipivotide tetraxetan in prostate cancer (PCa), sponsored by Peter MacCallum Cancer Centre. Started Dec 2023; status: recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05560659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05560659.